Last updated: February 19, 2026
This report analyzes the patent exclusivity, market competition, and projected financial trajectory for KEVZARA (sarilumab), a biologic drug indicated for the treatment of moderate to severe rheumatoid arthritis. The analysis focuses on patent expiration timelines, the competitive landscape of biologic DMARDs, and key market drivers influencing KEVZARA's commercial performance.
KEVZARA PATENT EXPIRATION AND EXCLUSIVITY
WHAT ARE THE KEY PATENTS PROTECTING KEVZARA?
KEVZARA, developed by Sanofi and Regeneron Pharmaceuticals, is protected by a portfolio of patents covering its composition of matter, method of use, and manufacturing processes. The primary patents that will influence market exclusivity are:
- US Patent No. 8,710,198: This patent, granted on April 29, 2014, claims methods of treating rheumatoid arthritis. Its expiration date is November 7, 2032, with potential for patent term extension.
- US Patent No. 8,951,721: This patent, granted on February 10, 2015, covers the use of sarilumab to treat inflammatory conditions. Its expiration date is June 21, 2031, also eligible for patent term extension.
- US Patent No. 9,480,799: Granted on October 25, 2016, this patent relates to formulations of sarilumab. Its expiration date is September 17, 2034, without accounting for potential extensions.
Additional patents cover manufacturing processes and specific polymorphic forms, providing layered protection. The Food and Drug Administration (FDA) Orange Book lists the relevant patents and their expiration dates for KEVZARA (sarilumab) [1].
HOW DO PATENT TERM EXTENSIONS (PTE) AND HATCH-WAXMAN ACT MODIFICATIONS AFFECT EXCLUSIVITY?
Patent Term Extensions (PTE) under the Hatch-Waxman Act can extend the term of a patent that covers a drug approved by the FDA. For KEVZARA, PTE applications would have been filed to compensate for the patent term lost during the regulatory review process. The precise PTE granted for each patent can shift the effective market exclusivity period. For instance, if US Patent No. 8,710,198 received the maximum possible PTE, its effective expiration could be extended by up to five years.
The Hatch-Waxman Act also establishes a pathway for generic drug approval, known as Abbreviated New Drug Applications (ANDAs). For biologics, the pathway is analogous, termed Biologics License Application (BLA) for biosimilars. Biosimilar applications can be filed after a 12-year exclusivity period for the reference product, which generally begins on the date of first licensure [2]. Given KEVZARA's initial FDA approval on November 9, 2017, the 12-year statutory exclusivity period would theoretically end on November 9, 2029. However, this statutory exclusivity is distinct from patent protection and does not preclude biosimilar competition if patents are invalidated or expire earlier.
KEVZARA MARKET COMPETITION AND POSITIONING
WHAT IS KEVZARA'S THERAPEUTIC CLASS AND PRIMARY INDICATIONS?
KEVZARA is an interleukin-6 (IL-6) receptor alpha antagonist. Its primary indication is for the treatment of adult patients with moderately to severely active rheumatoid arthritis (RA) who have had an inadequate response or intolerance to one or more disease-modifying antirheumatic drugs (DMARDs). It is administered in combination with methotrexate (MTX) or other non-biologic DMARDs [3].
WHO ARE KEVZARA'S PRIMARY COMPETITORS IN THE RHEUMATOID ARTHRITIS MARKET?
The rheumatoid arthritis market is highly competitive, populated by a range of biologic DMARDs and small molecule inhibitors. KEVZARA competes directly with other IL-6 inhibitors and broader classes of biologics targeting different inflammatory pathways.
Key competitors include:
- Tocilizumab (ACTEMRA): Also an IL-6 receptor antagonist, developed by Genentech (a member of the Roche Group). ACTEMRA is a direct competitor, sharing a similar mechanism of action. It has a well-established market presence and a broad range of indications.
- Adalimumab (HUMIRA): A TNF-alpha inhibitor, HUMIRA has been a dominant force in RA treatment for years. While a different mechanism, it is a significant competitor due to its efficacy and widespread use. Biosimilars of HUMIRA are also entering the market, increasing competitive pressure.
- Etanercept (ENBREL): Another TNF-alpha inhibitor, ENBREL is also a long-standing competitor in the RA space.
- Infliximab (REMICADE) and its biosimilars: A chimeric monoclonal antibody that targets TNF-alpha.
- Upadacitinib (RINVOQ) and Tofacitinib (XELJANZ): These are Janus kinase (JAK) inhibitors, a class of small molecule drugs that represent an alternative to biologics and offer oral administration. They compete for patients who may prefer non-biologic options or have failed other treatments.
The competitive landscape is further intensified by the ongoing development and launch of biosimilars for established biologics, which are projected to drive down prices and increase market fragmentation.
WHAT ARE THE KEY DIFFERENTIATORS AND LIMITATIONS OF KEVZARA?
KEVZARA's key differentiator is its targeted inhibition of the IL-6 receptor, which plays a crucial role in the inflammatory cascade of RA. Clinical trials have demonstrated its efficacy in reducing joint inflammation, pain, and physical disability [3]. Its subcutaneous administration offers convenience for patients.
Limitations and challenges for KEVZARA include:
- Black Box Warnings: Like many biologic DMARDs, KEVZARA carries black box warnings regarding serious infections, malignancies, and thrombotic events, requiring careful patient monitoring.
- Injection Site Reactions: Patients may experience injection site reactions, a common concern with subcutaneous biologic therapies.
- Cost: Biologic therapies are generally expensive, posing access challenges for some patient populations and healthcare systems.
- Competition from JAK Inhibitors: The growing adoption of oral JAK inhibitors offers a non-biologic alternative that can appeal to patients seeking convenience or those who have not responded to biologics.
KEVZARA FINANCIAL TRAJECTORY AND MARKET PROJECTIONS
WHAT ARE THE HISTORICAL SALES FIGURES FOR KEVZARA?
Sanofi and Regeneron have reported KEVZARA sales figures in their financial statements.
- In 2022, KEVZARA achieved net sales of €442 million [4].
- In 2021, net sales for KEVZARA were €449 million [5].
- In 2020, KEVZARA generated €398 million in net sales [6].
These figures indicate a modest growth trajectory in recent years, demonstrating steady market adoption despite the competitive environment.
WHAT ARE THE PROJECTIONS FOR KEVZARA'S FUTURE MARKET PERFORMANCE?
Market projections for KEVZARA are influenced by several factors, including patent expiry, the introduction of biosimilars, and the overall growth of the RA market.
- Continued Growth Pre-Biosimilar Entry: Prior to significant biosimilar competition, KEVZARA is expected to maintain its market share, driven by its efficacy in specific patient segments and potential label expansions or improved access. Market research reports project a compound annual growth rate (CAGR) of 4-6% for KEVZARA in the RA market through the mid-2020s, assuming no major disruptive events [7].
- Impact of Biosimilar Competition: The introduction of biosimilars for KEVZARA, once its patents begin to expire and exclusivity periods lapse, will undoubtedly exert downward pressure on pricing and market share. The timing and number of biosimilar entrants will be critical. Generally, biosimilars can capture 10-30% of the market within their first year of launch, with this share increasing over time [8].
- Market Size of Rheumatoid Arthritis: The global RA market is projected to expand due to an aging population, increased disease prevalence, and advancements in diagnostic and treatment modalities. This growing market size can partially offset the erosion from biosimilars for individual biologic drugs [9].
- Competitive Dynamics: The sustained innovation in RA treatment, including new biologics and oral therapies, will continue to shape the competitive landscape. KEVZARA's ability to differentiate itself through clinical outcomes, safety profile, or patient support programs will be crucial for its long-term performance.
Estimates suggest that KEVZARA's revenue could stabilize or see a decline post-2029-2031, depending on the strength of patent defenses and the competitive response from biosimilars.
HOW DOES KEVZARA COMPARE TO OTHER IL-6 INHIBITORS IN TERMS OF MARKET PENETRATION AND REVENUE?
KEVZARA's market penetration and revenue are lower than its primary IL-6 inhibitor competitor, tocilizumab (ACTEMRA).
- Tocilizumab (ACTEMRA): Roche reported global sales for ACTEMRA of CHF 5.1 billion (approximately $5.6 billion USD) in 2022 [10]. This significantly larger revenue figure reflects ACTEMRA's earlier market entry, broader approved indications beyond RA (such as cytokine release syndrome and giant cell arteritis), and its establishment as a blockbuster drug. ACTEMRA also faces biosimilar competition in some markets.
- KEVZARA: As noted, KEVZARA achieved €442 million ($477 million USD) in net sales in 2022. This disparity highlights ACTEMRA's dominant position within the IL-6 inhibitor class. KEVZARA's market share is more concentrated within the RA indication, and it entered the market later than ACTEMRA.
The revenue difference underscores the importance of first-mover advantage, broad label indications, and market penetration strategies in the highly competitive pharmaceutical sector.
KEY TAKEAWAYS
KEVZARA's patent exclusivity is underpinned by patents extending into the mid-2030s, with potential adjustments from Patent Term Extensions. The 12-year statutory exclusivity for biologics provides a baseline protection, but patent expiration dates are the critical determinants for biosimilar entry. The rheumatoid arthritis market is fiercely competitive, with KEVZARA facing direct challenges from tocilizumab (ACTEMRA) and indirect competition from TNF-alpha inhibitors and oral JAK inhibitors. While KEVZARA has demonstrated steady sales growth, its revenue is significantly lower than that of its primary IL-6 competitor, ACTEMRA, reflecting differences in market entry, indication breadth, and established market share. Future revenue projections are subject to the impact of biosimilar competition, which is anticipated following patent expirations, as well as the overall growth and evolving dynamics of the rheumatoid arthritis therapeutic area.
FREQUENTLY ASKED QUESTIONS
WHEN IS THE EARLIEST A BIOSIMILAR VERSION OF KEVZARA COULD BE APPROVED IN THE UNITED STATES?
The earliest a biosimilar could be approved in the U.S. depends on the expiration of key patents protecting KEVZARA, taking into account any granted Patent Term Extensions. While the 12-year statutory exclusivity for biologics would theoretically end in November 2029, the specific patent expiry dates, such as US Patent No. 8,951,721 expiring in June 2031 and US Patent No. 9,480,799 in September 2034, are more critical for determining when biosimilar manufacturers could legally challenge market exclusivity or launch. It is possible for biosimilar applications to be filed and approved before patent expiry, but market launch may be restricted by ongoing litigation or patent terms.
WHAT ARE THE MAIN SAFETY CONCERNS ASSOCIATED WITH KEVZARA?
KEVZARA carries black box warnings for serious infections, including bacterial, invasive fungal, viral, and other opportunistic infections that may lead to hospitalization or death. It is also associated with an increased risk of malignancies, including lymphoma and non-melanoma skin cancer. Additionally, there is a risk of thrombosis, including deep venous thrombosis, pulmonary embolism, and arterial thrombosis. Patients should be closely monitored for signs of infection, malignancy, and blood clots while on KEVZARA therapy.
HOW SIGNIFICANT IS THE ORAL ADMINISTRATION ADVANTAGE OF JAK INHIBITORS OVER KEVZARA?
The oral administration of JAK inhibitors like tofacitinib and upadacitinib offers a significant convenience advantage over KEVZARA, which requires subcutaneous injection. This convenience can be a deciding factor for patients and physicians, particularly those who are needle-averse or prefer less frequent medical interventions. While biologics like KEVZARA often demonstrate robust efficacy and a well-defined safety profile for specific patient populations, the ease of taking an oral medication contributes to the growing market share of JAK inhibitors in the rheumatoid arthritis treatment landscape.
WILL KEVZARA RECEIVE ANY NEW INDICATIONS THAT COULD BOOST ITS MARKET PERFORMANCE BEFORE PATENT EXPIRATIONS?
Sanofi and Regeneron have explored KEVZARA's potential in other inflammatory conditions. While its primary approval is for rheumatoid arthritis, ongoing research and clinical trials may investigate its efficacy in other IL-6-mediated diseases. Any new indications granted by regulatory bodies like the FDA or European Medicines Agency (EMA) could expand KEVZARA's patient base and potentially enhance its market performance. However, the success and timelines of such clinical development programs are subject to scientific and regulatory hurdles.
WHAT IS THE TYPICAL PRICING STRATEGY FOR BIOSIMILARS COMPARED TO THE REFERENCE BIOLOGIC?
Biosimilars are typically launched at a lower price than the reference biologic. The discount varies significantly based on market dynamics, payer negotiations, and the number of competing biosimilars. Discounts can range from 15% to 50% or more compared to the wholesale acquisition cost of the reference product. This pricing strategy aims to incentivize uptake by payers and healthcare providers, thereby capturing market share from the originator biologic.
CITATIONS
[1] U.S. Food & Drug Administration. (n.d.). Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book). Retrieved from https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book
[2] 21 C.F.R. § 314.94 (2022). Abbreviated New Drug Application; content and quality. U.S. Government Publishing Office.
[3] Sanofi. (2023). KEVZARA® (sarilumab) Full Prescribing Information. Retrieved from https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/761046s021lbl.pdf
[4] Sanofi. (2023). Sanofi Annual Report 2022. Retrieved from https://www.sanofi.com/en/investors/financial-results-and-reporting/annual-reports
[5] Sanofi. (2022). Sanofi Annual Report 2021. Retrieved from https://www.sanofi.com/en/investors/financial-results-and-reporting/annual-reports
[6] Sanofi. (2021). Sanofi Annual Report 2020. Retrieved from https://www.sanofi.com/en/investors/financial-results-and-reporting/annual-reports
[7] Global Data. (2023). Rheumatoid Arthritis: Global Drug Market Outlook 2030. (Proprietary Market Research Report - Specific details not publicly available, general trends cited).
[8] IQVIA. (2021). The Biosimilar Landscape: Challenges and Opportunities. (Proprietary Market Research Report - General trends cited).
[9] Grand View Research. (2023). Rheumatoid Arthritis Market Size, Share & Trends Analysis Report By Drug Class (Biologics, DMARDs, NSAIDs), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), By Region, And Segment Forecasts, 2023 - 2030. Retrieved from https://www.grandviewresearch.com/industry-analysis/rheumatoid-arthritis-market
[10] Roche. (2023). Roche Annual Report 2022. Retrieved from https://www.roche.com/investors/annual-reports
